Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432647
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-05-17
Brief Title:
A SAD and MAD Study of the Safety Tolerability and Pharmacokinetics of ATH-1105
Sponsor:
Athira Pharma
Organization:
Athira Pharma
Study Overview
Official Title:
ATH-1105 A Phase 1 Double-Blind Placebo-Controlled Single-and-Multiple-Oral-Dose Safety Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this Phase 1 interventional study is to assess the safety tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants
Detailed Description:
The study is a Phase 1 First-In-Human study consisting of two parts A and B Part A will comprise a single-dose double-blind placebo-controlled sequential-group design Part B will comprise a multiple-dose placebo-controlled sequential-group design
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None